Illumina, Inc. (NASDAQ:ILMN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Illumina, Inc. (NASDAQ:ILMN) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-one ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation, ten have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $159.45.

ILMN has been the subject of several research reports. Citigroup downgraded shares of Illumina from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $190.00 to $165.00 in a research note on Wednesday, December 11th. HSBC raised shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 target price for the company in a report on Thursday, October 17th. JPMorgan Chase & Co. raised their target price on shares of Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Barclays cut shares of Illumina from an “equal weight” rating to an “underweight” rating and reduced their target price for the stock from $130.00 to $100.00 in a report on Monday. Finally, Canaccord Genuity Group reduced their target price on shares of Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a report on Friday, February 7th.

Illumina Price Performance

NASDAQ ILMN opened at $101.78 on Friday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The firm’s 50 day moving average price is $134.32 and its 200-day moving average price is $135.12. Illumina has a 52-week low of $99.35 and a 52-week high of $156.66. The company has a market cap of $16.14 billion, a PE ratio of -13.25 and a beta of 1.10.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%. Sell-side analysts forecast that Illumina will post 4.42 EPS for the current fiscal year.

Institutional Trading of Illumina

Institutional investors have recently modified their holdings of the stock. Golden State Wealth Management LLC acquired a new stake in shares of Illumina in the fourth quarter valued at about $32,000. Versant Capital Management Inc boosted its position in Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 146 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new position in Illumina during the fourth quarter worth about $45,000. Assetmark Inc. boosted its position in Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after acquiring an additional 296 shares during the last quarter. Finally, Lee Danner & Bass Inc. acquired a new position in Illumina during the fourth quarter worth about $48,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.